Results 181 to 190 of about 298,611 (329)

Prenatal and Early Childhood Exposure to Antibiotics or Gastric Acid Inhibitors and Increased Risk of Epilepsy: A Nationwide Population‐Based Study

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Over 10 million children in the world have epilepsy, with an unknown cause in half of the cases. The gut microbiome has been associated with various neurological disorders, and certain drugs greatly disturb the microbiome. Our aim was to study the association of prenatal and childhood exposure (before the age of two) to antibiotics, proton pump ...
Unnur Gudnadottir   +4 more
wiley   +1 more source

Prevalence of Actionable Pharmacogenetic Genotype Frequencies, Cautionary Medication Use, and Polypharmacy in Community‐Dwelling Older Adults

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Older adults (65 years and over) frequently manage complex medication regimens and are vulnerable to adverse drug reactions and treatment inefficacies, some of which could be preventable with pharmacogenetics (PGx)‐guided prescribing. This study examined the prevalence of actionable PGx genotypes (i.e., those linked to a guideline that recommends a ...
Chad A. Bousman   +14 more
wiley   +1 more source

RETRACTED: Artificial intelligence for emergency medical care

open access: yesHealth Care Science, EarlyView., 2023
‘Applications of artificial intelligence in emergency medical service’. Abstract There is increasing research into the potential benefits of incorporating artificial intelligence (AI) and machine learning algorithms into emergency medical services. AI is finding new applications across a wide range of sectors, one of which is healthcare, where it is ...
Shivam Rajput   +2 more
wiley   +1 more source

Exploring the Association Between Intra‐Patient Variability in Trough Concentration of Pazopanib and Clinical Outcomes in Renal Cell Carcinoma and Soft Tissue Sarcoma Patients

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Pazopanib is an oral tyrosine kinase inhibitor used in patients with either metastatic renal cell carcinoma or soft tissue sarcoma. Pazopanib has a high interindividual variability in pharmacokinetics and pharmacodynamics and a well‐established exposure–response relationship. Therefore, therapeutic drug monitoring is recommended to improve the efficacy–
Amy Rieborn   +6 more
wiley   +1 more source

Studying waiting time in pharmacy: A strategy for improving patient satisfaction. [PDF]

open access: yesMethodsX
Yulia R   +4 more
europepmc   +1 more source

Optimizing Patient Registries for Regulatory Decision Making ‐ Key Learnings From an HMA/EMA Multistakeholder Workshop

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
The Joint Heads of Medicines Agencies and European Medicines Agency's (HMA/EMA) big data initiative paves the way for better integration of real‐world data, including data from patient registries, into regulatory decisions on medicines. This article focuses on the outcome of a two‐day multistakeholder workshop organized by EMA in 2024, which explored ...
Kelly Plueschke   +24 more
wiley   +1 more source

Attitudes and expectations toward medication review among community pharmacy customers in Germany: a cross-sectional study. [PDF]

open access: yesJ Pharm Policy Pract
Vogt CJ   +6 more
europepmc   +1 more source

CYP2C19 Polymorphisms and Clinical Outcomes Following Percutaneous Coronary Intervention in the Million Veteran Program

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
CYP2C19 loss‐of‐function (LOF) alleles decrease the antiplatelet effect of clopidogrel following percutaneous coronary intervention (PCI) in patients presenting with acute coronary syndrome (ACS). The impact of genotype in patients undergoing PCI for stable ischemic heart disease (SIHD) in real‐world populations is less clear.
Catherine Chanfreau‐Coffinier   +20 more
wiley   +1 more source

The evolution of outpatient dispensing services in Thailand's hospitals: what has been done and where are we heading? [PDF]

open access: yesJ Pharm Policy Pract
Chetsurakarn T   +5 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy